Thursday, March 30, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

U.S. Government to Conduct Sweeping Review of Biosecurity Policy Frameworks

by Global Biodefense Staff
February 28, 2022
Will Omicron Be More Contagious Than Delta?

Workbench in National Institute of Allergy and Infectious Diseases intramural laboratory. Credit: NIAID

The Biden Administration and National Institutes of Health (NIH) officials have initiated a review of the scope and effectiveness of U.S. biosecurity policy frameworks governing research with enhanced potential pandemic pathogens.

The review will be conducted through 2022 by the National Science Advisory Board for Biosecurity (NSABB), a Federal advisory committee that provides expert advice, guidance, and recommendations to the U.S. Government on biosecurity oversight of dual use research.

The review mission announced today builds upon the charge issued to the NSABB in January 2020 to provide recommendations on balancing security and public transparency when sharing information about research with enhanced potential pandemic pathogens; and evaluate and analyze the U.S. Dual Use Research of Concern (DURC) policies. The January 2020 charge was put on hold due to the rapid escalation of the COVID-19 pandemic to allow members to prioritize COVID-19 research response activities at their home institutions.

Recent outbreaks from viruses such as SARS-CoV-1, H1N1, Ebola, Zika, West Nile, and SARS-CoV-2 underscore the threats posed by infectious pathogens are not theoretical and the potential for societal disruption is substantial. Historically, the NSABB has played an important role in advising the federal government on strengthening oversight of life sciences research, and I want to thank the Board in advance for their expert input which will help ensure we continue to have robust policies in place that effectively balance science and security, and safely enable critical, life-saving research.

Lawrence A. Tabak, D.D.S., Ph.D., Acting Director, NIH

Research involving pathogens is vital for ensuring the United States is prepared to rapidly detect, respond to, and recover from future infectious disease threats. Such research can be inherently high risk given the possibility of biosafety lapses or deliberate misuse. However, not doing this type of research could impair the ability to prepare for and/or respond to future consequential biological threats.

NSABB Meeting Materials

Webcast

  • Recorded Webcast of NSABB Meeting February 28, 2022

Agenda

  • NSABB February 2022 Meeting Agenda 

Slides:

  • Hebbeler and Gastfriend – USG Perspectives on Life Science Research Oversight
  • Tabak and Jorgenson – 2022 Charge to the NSABB

READ ALSO:

  • Spurred by pandemic, U.S. government will revisit federal policies on risky virus research Science
  • NIH orders sweeping review of potentially risky experiments on viruses and other pathogens Washington Post
Tags: BiosafetyBSL-3BSL-4Dual Use Research of Concern (DURC)Editor PickLegislativeSelect Agents

Related Posts

Liverpool Synthetic Biology Lab Backed By 2M Award
Policy + Initiatives

Political Interference: White House Launches Framework to Protect Scientific Integrity

January 13, 2023
DARPA Pursues Advanced Threat-Detection for Crop Defense
Biosecurity

DARPA Pursues Advanced Threat-Detection for Crop Defense

January 3, 2023
Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.
Policy + Initiatives

Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.

December 7, 2022
State Department: Reducing Revisionist State Biological and Chemical Weapons Threats
CBRNE

State Department Sanctions Syrian Military Officials for Role in Ghouta Sarin Attack

October 24, 2022
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy